Nanolek biologics deal gives Green Cross route to Russia
This article was originally published in Scrip
Executive Summary
Following its entry into North America and China, South Korea's Green Cross is set to make inroads into the rapidly growing Russian pharmaceutical market through a strategic partnership with Nanolek to commercialize biologics.